Loading organizations...
Loading organizations...
Contego Medical is a technology company.
Contego Medical develops advanced medical devices to enhance patient safety and simplify complex vascular interventions. The company specializes in integrated embolic protection systems for carotid and peripheral vascular disease, featuring products like the Neuroguard IEP System for carotid stenting and Excipio Thrombectomy Devices. This technology integrates multiple functions into single-use systems, streamlining procedures and effectively capturing micro-emboli.
The company was founded by Ravish Sachar, MD, FACC. As an interventional cardiologist, Dr. Sachar identified critical unmet needs in patient protection and procedural efficiency during vascular interventions. This clinical insight propelled him to develop integrated embolic protection technology, establishing Contego Medical to address significant challenges in medical care.
Contego Medical’s products serve interventional cardiologists and vascular specialists. The company's vision is to improve patient outcomes by mitigating risks like stroke and cognitive impairment from embolic debris. They strive to provide integrated systems that deliver superior protection and efficiency for patients undergoing vascular interventions.
Contego Medical has raised $28.0M across 2 funding rounds.
Contego Medical has raised $28.0M in total across 2 funding rounds.
Contego Medical is a privately held medical device company based in Raleigh, NC, specializing in innovative endovascular devices that integrate embolic protection with treatment functions like balloons or stents on a single catheter.[1][2][3] This platform addresses unmet needs in carotid and peripheral vascular procedures by simplifying workflows, reducing procedure steps, improving patient outcomes, and lowering costs, serving interventional cardiologists and vascular specialists treating conditions like carotid artery stenosis and peripheral artery disease.[1][2][5] Key products include the Paladin® Carotid Post-Dilation Balloon System and Vanguard IEP™ Peripheral Balloon Angioplasty System, both CE marked and commercially available in select European markets since around 2015-2016, with recent U.S. expansion via an exclusive distribution agreement with Medtronic for carotid products.[1][3][5]
The company's growth momentum includes early commercial revenue starting in Q1 2016 (details private), clinical validation from the PERFORMANCE II study showing superior outcomes in carotid artery stenting (CAS), and a shift to broader U.S. market access through Medtronic, positioning it for scaled adoption in revascularization treatments.[3][5]
Founded in 2005, Contego Medical emerged from the vision of interventional cardiologists addressing gaps in embolic protection during endovascular procedures, where traditional methods required separate devices, complicating treatments and limiting patient access.[3] Ravish Sachar, MD, an interventional cardiologist and serial entrepreneur, co-founded and leads as CEO; he has advised multiple medtech firms and brings expertise from prior successes.[1][3] Jay Yadav, MD, a co-founder, further bolstered the team with his track record, including founding CardioMEMS (acquired by St. Jude Medical) and AngioGuard.[1][3]
The idea crystallized around integrating embolic protection directly with treatment tools, gaining early traction with CE Mark approvals for Paladin in Q2 2015 and Vanguard IEP, followed by European sales launch in 2016—pivotal moments that validated the technology and attracted venture capital for majority ownership.[1][3]
Contego stands out in the crowded medtech space through its integrated platform technology, which combines embolic protection with therapeutic functions (e.g., balloon dilation or stenting) on one catheter, enabling single-step procedures versus multi-device approaches.[1][2][3]
These features position Contego as a leader in patient-centric vascular interventions.[2][4]
Contego rides the wave of advancing endovascular therapies, where rising prevalence of peripheral and carotid vascular diseases—driven by aging populations and diabetes—demands safer, more efficient alternatives to open surgery.[1][2] Timing aligns with regulatory progress (CE marks) and partnerships like Medtronic, capitalizing on market forces such as reimbursement tailwinds for CAS and growing evidence for embolic protection to prevent periprocedural strokes.[5]
In the ecosystem, Contego influences medtech by pioneering integrated devices, potentially setting new standards of care and enabling broader embolic protection use, while validating clinician-founder models from serial entrepreneurs like Sachar and Yadav.[1][3] This counters fragmented legacy tools, fostering procedural simplification amid consolidation in vascular medtech.
Contego's Medtronic partnership marks a commercialization inflection, likely driving U.S. revenue growth and further trials to cement PERFORMANCE II data against competitors. Trends like AI-guided imaging and bioresorbable tech could enhance its platform, while expanding peripheral indications sustains momentum. Its influence may evolve from niche innovator to category leader, simplifying endovascular care as demographics amplify demand—echoing its founding promise of better outcomes through integration.[5]
Contego Medical has raised $28.0M in total across 2 funding rounds.
Contego Medical's investors include Hatteras Venture Partners, Lookout Capital, Medical Mutual, Mountain Group Partners.
Contego Medical has raised $28.0M across 2 funding rounds. Most recently, it raised $22.0M Other Equity in January 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 12, 2020 | $22.0M Other Equity | ||
| Apr 1, 2015 | $6.0M Series B | Hatteras Venture Partners | Lookout Capital, Medical Mutual, Mountain Group Partners |